News from Tokyo Headquarters

Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce 76 million USD in Funding for Manufacturing and Innovation Center

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility

Fujifilm to Expand its Viral Vector CDMO Services to Europe

Fujifilm wins Good Design Award with 27 products in a wide range of business fields

Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics, for a COVID-19 Vaccine Formulation

Centus Biotherapeutics Receives European Marketing Authorization for Equidacent^®, Biosimilar Avastin^®

Fujifilm launches droplet-shielding Mouthpiece “B1” and Endoscope Cover “P1”

Anti-influenza drug Avigan^® Tablet
Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

To realize a new therapeutic option for neuroendocrine tumors
Domestic marketing approval application filed for new radiopharmaceutical F-1515 (FUJIFILM Toyama Chemical)

FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate 

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio^® (adalimumab-fkjp)

Fujifilm partners with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan

Fujifilm Kyowa Kirin Biologics Announces Approval of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan

Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark

Fujifilm’s New AI-based Technology for Lung Nodule Detection Now Approved for Use in Japan

Fujifilm collaborates with Merck & Co., Inc., Kenilworth, N.J., U.S.A.  in a clinical trial for advanced solid tumor in combination therapy of FF-10832, a liposome drug candidate with KEYTRUDA^® (pembrolizumab)

Fujifilm to develop AI-based technology to aid COVID-19-induced pneumonia diagnosis and assess the effectiveness of treatments